Fujian manufacturing
Jinjiang manufacturing base
The Jinjiang manufacturing base supports peptide synthesis, purification, analytical testing, and production planning within the Fujian operating footprint.
Fujian Lumira Biotech Co., Ltd.
A peptide API manufacturer supporting global B2B supply.
LUMIRABIO is the brand of Fujian Lumira Biotech Co., Ltd. We focus on the metabolic peptide API field, professional organizations, qualification-led technical exchange, and molecule-specific evidence rather than consumer retail.
Product, site, scale, quality-system scope, documents, regulatory status, and target-market eligibility are confirmed for each inquiry and formal offer.
200 kg/monthAggregate factory capacity
Peptide API manufacturing capacity across the applicable factory scope.
2 U.S. warehouse pathwaysEligibility review
Los Angeles and New Jersey pathways are assessed for eligible inventory and each qualified order.
3 molecules in scopeFocused metabolic field
Semaglutide, Tirzepatide, and investigational Retatrutide.
Capacity planning brings together the molecule, material form, process route, site, batch size, specification, and production schedule.
Company profile
A focused peptide API platform built around connected decisions.
From its Fujian operating base, LUMIRABIO coordinates peptide API program review across technical scope, manufacturing planning, analytical evidence, and qualified supply.
The public portfolio is limited to Semaglutide, Tirzepatide, and investigational Retatrutide. This gives procurement, CMC, and quality teams one route to align identity, process, batch documents, destination, and delivery planning before a formal offer.
- 01
Field focus
The public scope covers three molecules within one metabolic peptide field, with a separate status and qualification path for investigational Retatrutide.
- 02
Technical coordination
Molecule, supplied form, route, responsible site, batch scale, specification, and schedule are reviewed as one project context.
- 03
Evidence planning
Specifications, methods, CoA scope, analytical support, traceability, and disclosure status are matched to the product, site, batch, market, and review stage.
- 04
Supply alignment
Available capacity, eligible inventory, local availability, release, packaging, documents, destination, and the Los Angeles or New Jersey dispatch route are confirmed before commitment.
R&D and manufacturing footprint
From molecule to kilogram scale. Stable, controllable, and scalable.
The Quanzhou–Xiamen–Jinmen Life & Health Silicon Valley, Jinjiang manufacturing base, peptide laboratory, and kilogram-scale pilot production form a connected Fujian footprint. Synthesis, purification, and analysis follow one development-to-production workflow.
A connected Fujian footprint for peptide research, process development, analytical review, pilot scale, and manufacturing coordination.
Peptide innovation laboratory
R&D and analytical review
An experienced R&D team supports peptide development, HPLC purification, and analytical review for applicable programs.
Kilogram-scale pilot production
Lab, pilot, and manufacturing scale
Program discussions can connect laboratory development, kilogram-scale pilot review, and commercial manufacturing planning; feasible scale remains project-specific.
A closer view of the park
A focused aerial view of the park buildings and internal roads.
Interior corridor
Room entrances and lighting along the interior corridor.
More site photographs4 views
Technology & innovation
SPPS, purification, and analysis in one technical loop.
Our R&D team specializes in solid-phase peptide synthesis (SPPS), molecule-specific modification strategy, preparative HPLC purification, and analytical review aligned to the applicable product and project.
Eligible programs may be evaluated from milligram development batches toward kilogram manufacturing batches. Feasible batch size and available capacity remain specific to the molecule, route, responsible site, equipment, and production schedule.
mg → kgFlexible batch planning
Development and manufacturing scale are assessed against the molecule, route, responsible site, equipment, and schedule.
99.0%–99.5%Target purity range
For suitable programs only; the agreed product specification and batch-specific CoA govern the supplied result.
LC-MS + MLTOrthogonal testing
LC-MS review and microbial-limit testing are included when applicable to the confirmed product and project specification.
- SPPS & modification
- Sequence assembly and peptide-modification strategy are reviewed against molecule length, hydrophobicity, impurity profile, and final-form requirements.
- Preparative HPLC
- Purification, pooling, isolation, counter-ion, and process-transfer readiness remain connected to the proposed manufacturing route.
- Orthogonal analytics
- LC-MS or intact-mass review is used where applicable. Microbial-limit testing is included only when it forms part of the confirmed product and project specification.
Capabilities in focus
Manufacturing
Capacity aligned to the project.
Route, equipment, batch scale, available capacity, and schedule are reviewed for the applicable molecule, site, and inquiry.
Review manufacturing
Quality and documents
Evidence matched to the decision.
Specifications, methods, CoA scope, and supporting records are reviewed by product, site, batch, and target market.
Review quality
Global supply
Two regional pathways. One confirmed order scope.
Los Angeles and New Jersey warehouse pathways may support eligible inventory; local availability, release, documents, carrier, and dispatch date are confirmed per order.
Review regional supplyU.S. regional supply
Warehouse support on both U.S. coasts.
Warehouse support through Los Angeles and New Jersey may be available for eligible inventory. A regional dispatch pathway is considered only after product eligibility, local availability, batch release, packaging, documents, carrier, and timing are confirmed.
U.S. West
Los Angeles, California
West Coast warehouse pathwayMay support eligible inventory after local availability, batch release, packaging, documents, carrier, destination, and timing are confirmed for the order.
U.S. East
New Jersey
East Coast warehouse pathwayMay support eligible inventory after local availability, batch release, packaging, documents, carrier, destination, and timing are confirmed for the order.
Order-specific confirmation
The stock mix changes with orders and replenishment. The applicable product, form, quantity, batch release, packaging, shipping documents, carrier, destination, commercial terms, and dispatch date must align for the qualified order.
Company location
A clear address for qualified business visits.
LUMIRABIO is the brand of Fujian Lumira Biotech Co., Ltd. The address below identifies the Fujian operating and production base for qualified B2B coordination.
Legal entityFujian Lumira Biotech Co., Ltd.
Company / production addressNo. 6 Guangming Road, Lingyuan, Jinjiang, Quanzhou, Fujian, China
Map positioning is for location reference. Site access, responsible entity, production scope, and visit arrangements should be confirmed in advance.